Compare State Street Real Estate Select Sector SPDR ETF (XLRE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street Real Estate Select Sector SPDR ETF vs Zoetis Inc — how do they compare? State Street Real Estate Select Sector SPDR ETF trades at $41.61 (market cap $7.61B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 4× State Street Real Estate Select Sector SPDR ETF's market cap, and Zoetis Inc pays a 2.9% dividend while State Street Real Estate Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street Real Estate Select Sector SPDR ETF for 75 Days and Zoetis Inc for 70 Days on average.
| XLRE | ZTS | |
|---|---|---|
Market Cap | $7.61B | $30.20B |
Volume | 7,876,569 | 6,175,327 |
Sector | Sector/Thematic | Health |
52-Week High | $46.01 | $147.53 |
52-Week Low | $40.01 | $69.09 |
Typical Hold Time | 75 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLRE, the State Street Real Estate Select Sector SPDR ETF, trades at $41.61, up 2.56% on the day, but technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. The ETF offers a low expense ratio of 0.08% and focuses on 30 U.S. large-cap real estate holdings, providing concentrated exposure to the domestic market. Recent news highlights comparisons with global real estate ETFs and discussions on value amid rising bond yields.
The outlook for XLRE is cautious due to bearish technicals and sensitivity to interest rate fluctuations, though its low cost and U.S. focus present a streamlined real estate investment option. Key risks include macroeconomic pressures from potential rate hikes and sector underperformance relative to digital infrastructure themes, requiring careful monitoring of Fed policy and real estate market dynamics.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
